

CSD/BSE&NSE/BM/2024-25
September 19, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Press Release regarding change of Directorate

In furtherance to our disclosure dated September 19, 2024, we are enclosing herewith the press release regarding change of Directorate.

This is for your information and record.

Thanking you.

Yours faithfully,
For Suven Pharmaceuticals Limited

Kundan Kumar Jha
Company Secretary, Compliance Officer
and Head-Legal

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Suven Pharmaceuticals names Mr. Vivek Sharma as Executive Chairman

Current Exec-Chair Mr. Vaidheesh Annaswamy to transition to Advisory council

Hyderabad, September 19, 2024

Suven Pharmaceuticals Ltd. (BSE: 530239, NSE: SUVENPHAR), announced the appointment of Mr. Vivek Sharma as the new Executive Chairman, effective 20th Sep 2024, as Mr. Vaidheesh Annaswamy decides to transition from the Board and becomes the Vice-Chair of Suven's Advisory council.

About Mr. Vivek Sharma

Vivek brings tremendous CDMO and leadership expertise to Suven, acquired across his roles as CEO of Piramal Pharma solutions (2014-19) and as Chairman & CEO of Adare Pharma solutions, a technology CDMO business (2020-22). He was also CEO of Decision Resources Group, a healthcare analytics company (2019-20) and CEO of Saama, an AI clinical analytics company (2022-24). Vivek was recognized as 'Global CEO of the Year' by CPhI Pharma Awards in 2015. Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform. Vivek earned an Executive MBA from the Thunderbird School of Global Management. He is also a Chartered Accountant and a Certified Public Accountant (CPA).

Pankaj Patwari, Non-Exec Director, Suven and Managing Director, Advent International said, "On behalf of the entire Suven board, I am delighted to welcome Vivek to the Suven family. We are confident that the business will immensely benefit from Vivek's many years of CDMO and leadership experience, which will enable us to unlock many future growth opportunities. We also extend our gratitude to Vaidheesh for his valuable contribution over the past year as the Executive Chair."

Vivek Sharma said "This an exciting time for the CDMO industry and especially for Indian players. Within this landscape, Suven, with its track record and especially its technology capabilities, is well placed to capture market tailwinds. I'm very excited to take up this role at Suven, where our work shall contribute to transforming patient lives. I look forward to being an integral part of Suven's incredible growth journey, where we shall make a meaningful impact through innovation and collaboration."

Vaidheesh Annaswamy said "Given the stage of my career, I have decided to move to an advisory role where I shall continue to contribute to Suven's growth strategy as Vice Chair of the Advisory Council. I am glad to have Vivek as my successor. Vivek brings tremendous industry experience, and will continue the efforts I had initiated, to make Suven one of the leading tech-led diversified CDMOs."

In his role as the Executive Chairman, Vaidheesh has successfully overseen the management transition at Suven, built a professional team and led the development of the 5-year strategy. He has also set the stage for the proposed merger of Cohance Lifesciences into Suven (ongoing) and has successfully led the acquisition of Sapala Organics.

For more information, please visit www.suvenpharm.com OR contact:

Cyndrella Carvalho, Head - Investor Relations,

Suven Pharmaceutical Ltd

Tel: 040 2354 3311

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com

rishab@cdr-india.com

Disclaimer. Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.